HRP20100195T1 - 1,4-dihidropiridinski kondenzirani heterocikli, postupak njihovog dobivanja, upotreba i pripravci koji ih sadrže - Google Patents
1,4-dihidropiridinski kondenzirani heterocikli, postupak njihovog dobivanja, upotreba i pripravci koji ih sadrže Download PDFInfo
- Publication number
- HRP20100195T1 HRP20100195T1 HR20100195T HRP20100195T HRP20100195T1 HR P20100195 T1 HRP20100195 T1 HR P20100195T1 HR 20100195 T HR20100195 T HR 20100195T HR P20100195 T HRP20100195 T HR P20100195T HR P20100195 T1 HRP20100195 T1 HR P20100195T1
- Authority
- HR
- Croatia
- Prior art keywords
- heteroaryl
- compound according
- aryl
- substituted
- alkyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 125000001424 substituent group Chemical group 0.000 claims abstract 14
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 10
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 5
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 2
- 229910052794 bromium Inorganic materials 0.000 claims abstract 2
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical group C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims 1
- 101100167062 Caenorhabditis elegans chch-3 gene Chemical group 0.000 claims 1
- 101100134927 Gallus gallus COR8 gene Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 229940127554 medical product Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 101100439662 Arabidopsis thaliana CHR5 gene Proteins 0.000 abstract 1
- -1 O -allyl Chemical group 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05291558A EP1746097B1 (en) | 2005-07-20 | 2005-07-20 | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100195T1 true HRP20100195T1 (hr) | 2010-05-31 |
Family
ID=35510894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100195T HRP20100195T1 (hr) | 2005-07-20 | 2010-04-07 | 1,4-dihidropiridinski kondenzirani heterocikli, postupak njihovog dobivanja, upotreba i pripravci koji ih sadrže |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US8163768B2 (pt) |
| EP (2) | EP1746097B1 (pt) |
| JP (2) | JP2009501778A (pt) |
| KR (1) | KR101286796B1 (pt) |
| CN (1) | CN101243087B (pt) |
| AR (1) | AR054845A1 (pt) |
| AT (2) | ATE455115T1 (pt) |
| AU (1) | AU2006273692B8 (pt) |
| BR (1) | BRPI0614002A2 (pt) |
| CA (1) | CA2615700C (pt) |
| CR (1) | CR9663A (pt) |
| CY (1) | CY1109964T1 (pt) |
| DE (1) | DE602005018911D1 (pt) |
| DK (1) | DK1746097T3 (pt) |
| DO (1) | DOP2006000175A (pt) |
| EA (1) | EA016815B1 (pt) |
| EC (1) | ECSP078062A (pt) |
| ES (1) | ES2339676T3 (pt) |
| HN (1) | HN2008000088A (pt) |
| HR (1) | HRP20100195T1 (pt) |
| IL (1) | IL188861A0 (pt) |
| MA (1) | MA29634B1 (pt) |
| MX (1) | MX2008000902A (pt) |
| MY (1) | MY148617A (pt) |
| NO (1) | NO20080831L (pt) |
| NZ (1) | NZ592766A (pt) |
| PE (2) | PE20070212A1 (pt) |
| PL (1) | PL1746097T3 (pt) |
| PT (1) | PT1746097E (pt) |
| RS (1) | RS51351B (pt) |
| SI (1) | SI1746097T1 (pt) |
| TN (1) | TNSN08020A1 (pt) |
| TW (1) | TWI386411B (pt) |
| UA (1) | UA98928C2 (pt) |
| UY (1) | UY29685A1 (pt) |
| WO (1) | WO2007012972A2 (pt) |
| ZA (1) | ZA200800542B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2945535B1 (fr) | 2009-05-18 | 2011-06-10 | Sanofi Aventis | Compose anticancereux et composition pharmaceutique le contenant |
| FR2967413A1 (fr) * | 2010-11-17 | 2012-05-18 | Sanofi Aventis | Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora. |
| KR102190848B1 (ko) | 2012-05-15 | 2020-12-15 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 화합물 및 조성물 |
| MX2014013376A (es) | 2012-05-15 | 2015-08-14 | Novartis Ag | Derivados de benzamida para inhibir la actividad de abl1, abl2, y bcr-abl1. |
| WO2013171640A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| RS57177B1 (sr) | 2012-05-15 | 2018-07-31 | Novartis Ag | Derivati benzamida za inhibiranje aktivnosti abl1, abl2 i bcr-abl1 |
| HUE043853T2 (hu) * | 2012-10-12 | 2019-09-30 | Broad Inst Inc | GSK3 inhibitorok és eljárások azok alkalmazására |
| US10017520B2 (en) | 2014-12-10 | 2018-07-10 | Massachusetts Institute Of Technology | Myc modulators and uses thereof |
| EP4212532A3 (en) | 2015-04-30 | 2023-09-27 | Memorial Sloan Kettering Cancer Center | Mitragynine analogs and uses thereof |
| RU2619932C1 (ru) * | 2015-11-25 | 2017-05-22 | федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДО[3,4-е]ПИРИМИДИНЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ |
| WO2017124087A1 (en) | 2016-01-15 | 2017-07-20 | Memorial Sloan-Kettering Cancer Center | Anti-parasitic compounds and uses thereof |
| MX2018009913A (es) | 2016-02-16 | 2018-11-29 | Massachusetts Inst Technology | Aglutinantes max como moduladores myc y sus usos. |
| US11203601B2 (en) | 2017-04-05 | 2021-12-21 | The Broad Institute, Inc. | Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU747705C (en) * | 1997-12-13 | 2004-09-23 | Bristol-Myers Squibb Company | Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors |
| WO2001036422A1 (en) | 1999-11-19 | 2001-05-25 | Abbott Laboratories | Tricyclic dihydropyrimidine potassium channel openers |
| CA2402179A1 (en) | 2000-03-03 | 2001-09-13 | Abbott Laboratories | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| US6538004B2 (en) | 2000-03-03 | 2003-03-25 | Abbott Laboratories | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| KR20030076650A (ko) | 2001-02-02 | 2003-09-26 | 미쯔비시 웰 파마 가부시키가이샤 | 디하이드로피라졸로피리딘 화합물 및 그의 약학적 용도 |
| FR2823854A1 (fr) | 2001-04-18 | 2002-10-25 | Centre Nat Rech Scient | Nouveau procede de criblage d'inhibiteurs de la liaison entre la proteine oxyde nitrique synthase neuronale et la proteine inhibitrice de l'oxyde nitrique synthase neuronale |
| FR2825091B1 (fr) * | 2001-05-23 | 2003-07-04 | Servier Lab | Nouveaux derives tricycliques de dihydro-quinnoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7037902B2 (en) * | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| SE0301371D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | New Compounds |
| JP2007500249A (ja) * | 2003-06-13 | 2007-01-11 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ホスファチジルイノシトール３−キナーゼ阻害活性を有する化合物及びその使用方法 |
-
2005
- 2005-07-20 RS RSP-2010/0159A patent/RS51351B/en unknown
- 2005-07-20 PT PT05291558T patent/PT1746097E/pt unknown
- 2005-07-20 DK DK05291558.4T patent/DK1746097T3/da active
- 2005-07-20 SI SI200530964T patent/SI1746097T1/sl unknown
- 2005-07-20 AT AT05291558T patent/ATE455115T1/de active
- 2005-07-20 PL PL05291558T patent/PL1746097T3/pl unknown
- 2005-07-20 ES ES05291558T patent/ES2339676T3/es active Active
- 2005-07-20 DE DE602005018911T patent/DE602005018911D1/de active Active
- 2005-07-20 EP EP05291558A patent/EP1746097B1/en active Active
-
2006
- 2006-07-18 MY MYPI20063429A patent/MY148617A/en unknown
- 2006-07-18 JP JP2008522098A patent/JP2009501778A/ja not_active Withdrawn
- 2006-07-18 AU AU2006273692A patent/AU2006273692B8/en not_active Ceased
- 2006-07-18 CN CN2006800303826A patent/CN101243087B/zh not_active Expired - Fee Related
- 2006-07-18 PE PE2006000862A patent/PE20070212A1/es not_active Application Discontinuation
- 2006-07-18 MX MX2008000902A patent/MX2008000902A/es active IP Right Grant
- 2006-07-18 EA EA200800374A patent/EA016815B1/ru not_active IP Right Cessation
- 2006-07-18 AT AT06808922T patent/ATE521611T1/de not_active IP Right Cessation
- 2006-07-18 BR BRPI0614002-5A patent/BRPI0614002A2/pt not_active IP Right Cessation
- 2006-07-18 KR KR1020087003945A patent/KR101286796B1/ko not_active IP Right Cessation
- 2006-07-18 ZA ZA200800542A patent/ZA200800542B/xx unknown
- 2006-07-18 UA UAA200802146A patent/UA98928C2/ru unknown
- 2006-07-18 PE PE2010000153A patent/PE20100718A1/es not_active Application Discontinuation
- 2006-07-18 WO PCT/IB2006/002734 patent/WO2007012972A2/en active Application Filing
- 2006-07-18 EP EP06808922A patent/EP1910366B1/en active Active
- 2006-07-18 CA CA2615700A patent/CA2615700C/en not_active Expired - Fee Related
- 2006-07-18 AR ARP060103065A patent/AR054845A1/es not_active Application Discontinuation
- 2006-07-18 NZ NZ592766A patent/NZ592766A/xx not_active IP Right Cessation
- 2006-07-19 TW TW095126453A patent/TWI386411B/zh not_active IP Right Cessation
- 2006-07-20 UY UY29685A patent/UY29685A1/es unknown
- 2006-07-20 DO DO2006000175A patent/DOP2006000175A/es unknown
-
2007
- 2007-12-27 EC EC2007008062A patent/ECSP078062A/es unknown
-
2008
- 2008-01-15 CR CR9663A patent/CR9663A/es unknown
- 2008-01-15 US US12/014,516 patent/US8163768B2/en active Active
- 2008-01-16 MA MA30580A patent/MA29634B1/fr unknown
- 2008-01-17 IL IL188861A patent/IL188861A0/en unknown
- 2008-01-18 TN TNP2008000020A patent/TNSN08020A1/en unknown
- 2008-01-21 HN HN2008000088A patent/HN2008000088A/es unknown
- 2008-02-15 NO NO20080831A patent/NO20080831L/no not_active Application Discontinuation
-
2010
- 2010-04-07 HR HR20100195T patent/HRP20100195T1/hr unknown
- 2010-04-09 CY CY20101100327T patent/CY1109964T1/el unknown
-
2012
- 2012-11-05 JP JP2012243375A patent/JP2013063987A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100195T1 (hr) | 1,4-dihidropiridinski kondenzirani heterocikli, postupak njihovog dobivanja, upotreba i pripravci koji ih sadrže | |
| HRP20161498T1 (hr) | Inhibitori kinaza i njihova upotreba u liječenju raka | |
| HRP20210926T1 (hr) | Derivati 1h-indazol-3-karboksamida i povezani spojevi kao inhibitori faktora d za liječenje bolesti karakteriziranih pojačanom djelatnošću sustava komplemenata, kao npr. imunološki poremećaji | |
| HRP20090280T1 (en) | Phenoxyacetic acid derivatives | |
| JP2017515850A (ja) | ピロリジン−２，５−ジオン誘導体、医薬組成物およびｉｄｏ１阻害剤としての使用のための方法 | |
| EA200701991A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО [1,5-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ | |
| WO2008041053A3 (en) | Inhibitors of vegf receptor and hgf receptor signaling | |
| MX2010007746A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de diana de rapamicina de mamifero quinasa y fosfatidilinositol quinasa y su sintesis. | |
| MX2010004260A (es) | Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa. | |
| WO2007058832A3 (en) | Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors | |
| NZ603643A (en) | Purinone derivative | |
| MY145177A (en) | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. | |
| TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| AR060316A1 (es) | Azaindoles de utilidad como inhibidores de janus quinasas | |
| IN2014CN04310A (pt) | ||
| WO2006040569A8 (en) | Thiophene amide compounds for use in the treatment or prophylaxis of cancers | |
| WO2007122634A3 (en) | Pyrimidinediones as tyrosine kinase inhibitors | |
| SG162722A1 (en) | N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | |
| MX2010013682A (es) | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. | |
| CA2521732A1 (en) | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | |
| HRP20110344T1 (hr) | Derivati dihidropiridina | |
| HRP20070498T3 (en) | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| RS51557B (en) | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS ALFA 7 NICOTINE ACETYLHOLINE RECEPTORS | |
| MY129329A (en) | 6,7-DIHYDRO-5H-PYRAZOLO[1,2-a]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES |